-
1.发明申请公开(公告)号：US20210369695A1
公开(公告)日：2021-12-02
申请号：US17043442
申请日：2018-11-27
发明人： Liang Chang DONG , Shizhong ZHANG , Yan JIAO , Danyong ZHANG , Wenfang ZHAO , Jingmin SHI
摘要： Disclosed is a pharmaceutical composition containing dabigatran etexilate and a preparation method thereof. The pharmaceutical composition comprises a pharmaceutically active ingredient, dabigatran etexilate and/or dabigatran etexilate mesylate, and an polymer of polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft copolymer. The mass ratio of the two is 1:0.23 to 1:3. The pharmaceutical composition not only increases the bioavailability of the pharmaceutically active ingredient, but also reduces absorption variability, and provides a more stable concentration of dabigatran in plasma, thereby reducing adverse side effects.
-
2.发明公开公开(公告)号：US20240269443A1
公开(公告)日：2024-08-15
申请号：US18419536
申请日：2024-01-22
发明人： Liang Chang DONG , Ming FAN , Wenbo MA , Jingmin SHI , Danyong ZHANG , Gang WU
IPC分类号： A61M31/00
CPC分类号： A61M31/002 , A61M2205/0216 , A61M2205/0233 , A61M2205/025 , A61M2207/10 , A61M2210/0637
摘要： The present disclosure relates to an oral retention device and an osmotic pump tablet, preparation method therefor and application thereof. The medicinal tablet is inserted into the oral retention device to form a pharmaceutical device composition. The pharmaceutical device composition is fixed on the matching teeth in the oral cavity to achieve sustained release of the drug within a certain period of time. A high-dose osmotic pump tablet of the present disclosure with the absorption window of active pharmaceutical ingredients limited to the upper gastrointestinal tract has a high drug loading capacity and can achieve a good therapeutic effect.
-
3.发明公开公开(公告)号：US20230310401A1
公开(公告)日：2023-10-05
申请号：US18207751
申请日：2023-06-09
发明人： Liang Chang DONG , Shizhong ZHANG , Yan JIAO , Danyong ZHANG , Wenfang ZHAO , Jingmin SHI
IPC分类号： A61K31/4439 , A61K9/16
CPC分类号： A61K31/4439 , A61K9/1641 , A61K9/1635 , A61K9/1694 , A61K9/1652 , A61K9/1617
摘要： Disclosed is a pharmaceutical composition containing dabigatran etexilate and a preparation method thereof. The pharmaceutical composition comprises a pharmaceutically active ingredient, dabigatran etexilate and/or dabigatran etexilate mesylate, an amphiphilic polymer of polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft copolymer, and a hydrophilic polymer of polyoxyethylene-polyoxypropylene glycol block copolymer. The mass percentage of the active pharmaceutical ingredient in the pharmaceutical composition is 5 wt % to 60 wt %; the mass percentage of the amphiphilic polymer in the pharmaceutical composition is 3 wt % to 40 wt %; and the mass percentage of the hydrophilic polymer in the pharmaceutical composition is 10 wt % to 90 wt %. The pharmaceutical composition not only increases the bioavailability of the pharmaceutically active ingredient, but also reduces absorption variability, and provides a more stable concentration of dabigatran in plasma, thereby reducing adverse side effects.
-
4.发明申请公开(公告)号：US20210169811A1
公开(公告)日：2021-06-10
申请号：US17101706
申请日：2020-11-23
发明人： Liang Chang DONG , Xishan CHEN , Jingmin SHI , Danyong ZHANG , Gang WU
IPC分类号： A61K9/28 , A61K31/198 , A61K45/06 , A61K9/20 , A61K9/00
摘要： Disclosed are a controlled-release dosage form with an absorption window in the upper gastrointestinal tract and a preparation method therefor, wherein the controlled-release dosage form comprises a controlled-release platform and a retention platform. The controlled-release platform is a pharmaceutical composition comprising a tablet core and a coating membrane; and the retention platform holds the controlled-release platform in the oral cavity. The operation steps of the controlled-release dosage form are as follows: placing the controlled-release platform in the retention platform, and fixing the retention platform on matching teeth in the oral cavity; taking out the controlled-release dosage form after 4-24 hours and replacing same with a new controlled-release platform; and re-fixing the retention platform on the matching teeth in the oral cavity to achieve the sustained and stable release of drugs.
-
-
-
搜索结果
4 条记录 (耗时 0.025 秒)
